Anti-infectious carbohydrates

• US 20050004070A1
• Filed: 09/25/2002
• Published: 01/06/2005
• Est. Priority Date: 09/25/2001
• Status: Active Grant

• Current Assignee: nv nutricia
• Original Assignee: nv nutricia
• Inventors: Finke, Berndt, Slaghuis, Jorg, Schmitt, Joachim, Stahl, Bernd, Goebel, Werner
• Granted Patent: US 7,858,595 B2
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

Neutral straight-chain or branched oligosaccharides for preventing the invasion and infection of mammal cells by pathogens and for fighting diseases caused by such pathogens are disclosed. Food, dietetic products and pharmaceutical agents containing oligosaccharides consist of a base unit of formula (I), and between 0 and 19 other units of formula (II), which are linked directly or indirectly to the base unit. Gal represents a galactose monosaccharide unit; Glc represents a glucose monosaccharide unit; HexNAc rpresents an N-acetylated galactosamine or glucosamine monosaccharide unit (GalNAc or GlcNAc); R independently represent a β 1-3 or β 1-6 glycosidic link to HexNAc monosaccharide of the next [Gal-HexNAc] unit (II), and on a terminal [Gal-HexNAc] unit, or R are not present; and a terminal [Gal-HexNAc] unit, wherein R represent a deoxyhexose radical, can have another deoxyhexose radical on the HexNAc monosaccharide unit.

Claims

1. A composition of neutral straight-chain or branched oligosaccharides of a base unit of the following general formula I:

2. A composition according to claim 1, characterized in that the oligosaccharides correspond to the following general formula:

3. A composition according to claim 1, characterized in that the oligosaccharides meet at least one of the following criteria:

the deoxyhexose residue, if present, of the galactose monosaccharide unit of the terminal [Gal-HexNAc] unit is linked to it in an α

1-2 glycosidic bond,

the deoxyhexose residue, if present, of the galactose monosaccharide unit of the terminal [Gal-HexNAc] unit is a rhamnose or fucose residue,

the further deoxyhexose residue, if present, of the HexNAc monosaccharide unit of the terminal [Gal-HexNAc] unit is linked to it in an α

1-3 or α

l-4 glycosidic bond,

the further deoxyhexose residue, if present, of the HexNAc monosaccharide unit of the terminal [Gal-HexNAc] unit is a rhamnose or fucose residue.

4. A composition according to claim 1, characterized in that (Gal β

1-3GlcNAc β

1-3Gal β

1-4Glc, LNT) is used as the oligosaccharide, lacto-N-tetraose.

5. A composition according to claim 4, characterized in that the lacto-N-tetraose is derivatized in an α

1-2 glycosidic bond at the terminal galactose monosaccharide unit by means of fucose, and is lacto-N-fucopentaose I (LNFP I).

6. A composition according to claim 1, characterized in that the oligosaccharides are immobilized on or adsorbed in an inert carrier.

7. A composition according to claim 6, characterized in that the carrier is a peptide, a protein, a lipid, a polymer or a bio-polymer.

8. A composition according to claim 1, characterized in that the oligosaccharides are incorporated in a liquid or solid food (with the exception of human milk), dietetic compositions or pharmaceutical compositions for administration to a human or an animal, or serve in the production of such an agent.

9. A composition according to claim 8, characterized in that the pharmaceutical compositions is suitable for oral, lingual, nasal, bronchial, vaginal, topical (skin and mucosa) or per os administration, or for administration by means of a probe into the stomach of a human or an animal.

10. A composition according to claim 1, characterized in that the oligosaccharides are administered in an amount of at least 1 mg per kg of body weight and per day to a human or an animal, but not in the form of human milk.

11. A composition according to claim 1, characterized in that the pathogens are invasive Gram-positive and Gram-negative pathogenic bacteria, in particular listeria bacteria, and pathogenic viruses.

12. A food, dietetic and pharmaceutical compositions containing at least one oligosaccharide described in claim 1, wherein the pharmaceutical compositions in addition may contain a usual auxiliary agent or several usual auxiliary agents, including diluents, moisturizing agents, thickening agents, flavoring agents, sweetening agents and carriers, as well as one further active agent or several further active agents.

13. A method of reducing or preventing the invasion and infection of mammal cells by pathogens, and of combating diseases in humans and animals caused by such pathogens;

characterized in that at least one oligosaccharide, or a composition according to claim 10 is administered, but not in the form of human milk, to a human or an animal, in particular in an amount that at least 1 mg of oligosaccharide per kg of body weight and per day is given to the human or the animal.

14. A method of reducing or preventing the invasion and infection of mammal cells by pathogens, and of combating diseases in humans and animals caused by such pathogens;

characterized in that at least one oligosaccharide, or a composition according to claim 11 is administered, but not in the form of human milk, to a human or an animal, in particular in an amount that at least 1 mg of oligosaccharide per kg of body weight and per day is given to the human or the animal